Biomerica Receives MHRA Registration for hp+detect(TM), Allowing Commercial Sales in Great Britain
MWN-AI** Summary
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic products, has achieved a significant milestone by securing registration from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for its hp+detect™ test, which identifies Helicobacter pylori (H. pylori) infections. This approval enables Biomerica to market hp+detect™ across laboratories in Great Britain, pursuing opportunities in the UK diagnostic laboratory market through active discussions with potential local partners.
H. pylori infection, affecting approximately 35% of the U.S. population and 45% of individuals in Europe’s largest countries, is linked to peptic ulcers and is recognized as a Class 1 carcinogen by the World Health Organization. Notably, it is a prominent risk factor for gastric cancer, a leading cause of cancer-related deaths globally. The emergence of antibiotic-resistant bacteria, including H. pylori, heightens the necessity for reliable, non-invasive diagnostic solutions to facilitate timely treatment initiation.
Zack Irani, CEO of Biomerica, emphasized the importance of this registration, stating it enhances the company's footprint in a crucial market characterized by a notable prevalence of H. pylori. The hp+detect™ test will not only aid clinicians in diagnosing infections but also in monitoring treatment efficacy, ultimately contributing to better health outcomes in a landscape of rising antimicrobial resistance.
Biomerica’s strategic focus lies in gastrointestinal and inflammatory diseases, and the launch of hp+detect™ strengthens its portfolio of diagnostic and therapeutic tools. As the company navigates the complexities of international market entry, it acknowledges potential challenges, including regulatory hurdles and competition, while it strives to advance healthcare solutions that improve patient outcomes and reduce overall healthcare costs.
MWN-AI** Analysis
Biomerica, Inc. (NASDAQ: BMRA) has made significant strides with the recent receipt of MHRA registration for its innovative hp+detect™ diagnostic test, which detects Helicobacter pylori (H. pylori) infections. This regulatory approval marks an important milestone for Biomerica and opens the door to commercial sales in the UK market, a critical territory given the high prevalence of H. pylori infections.
The WHO categorizes H. pylori as a Class 1 carcinogen, highlighting the clinical significance of accurate and timely diagnostics. With about 44% of the global population affected by H. pylori, Biomerica’s entry into the UK market is timely, addressing a pressing healthcare need. The hp+detect™ product not only aids in diagnosis but also in monitoring treatment efficacy against a bacterium that drives numerous gastrointestinal diseases, including gastric cancer.
Investors should view this development positively, as it positions Biomerica strategically within a lucrative market. The growing discussions with UK partners to penetrate the diagnostic laboratory space further enhances the company's potential for revenue growth. It may also provide Biomerica with valuable insights into market dynamics and customer needs, which can be leveraged for futures sales.
However, caution is warranted. The competitive landscape for diagnostic products is robust, with larger corporations vying for market share and possessing substantial resources. Biomerica must swiftly secure partnerships to establish its footprint in the UK while ensuring the availability and adoption of hp+detect™ among healthcare providers.
In summary, while Biomerica's prospects appear promising with the MHRA approval and subsequent commercialization efforts, potential investors should remain cognizant of market competition and operational challenges. Continued monitoring of the firm’s strategic moves will be key in assessing its investment viability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
- Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
- Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.
IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced that it has received official registration from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for its hp+detect™ diagnostic test that detects Helicobacter pylori (H. pylori) bacteria. This product will now be marketed to labs throughout the UK for the detection of H. pylori infection in patients.
The Biomerica hp+detect™ product detects H. pylori bacteria, which is estimated to infect 35% of the U.S. population and 45% of the population in Europe’s five largest countries. H. pylori infection is the strongest known risk factor for gastric cancer, which is the third most common cause of cancer-related death worldwide. The WHO has designated H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health. Physicians and medical centers will be able to use hp+detect™ to diagnose H. pylori infection and monitor efficacy of treatments used to eradicate the infection.
H. pylori is one of the most prevalent bacterial infections worldwide, affecting an estimated 44% of the global population. It is the leading cause of peptic ulcer disease and a primary driver of gastric cancer — the third most common cause of cancer-related death globally. In the United Kingdom, H. pylori infection remains a significant public health burden, and the availability of accurate, non-invasive diagnostic tools is critical to enabling timely clinical intervention and appropriate antibiotic therapy in an era of increasing antimicrobial resistance.
“Receiving MHRA registration for hp+detect™ is a meaningful commercial milestone that expands our international reach into the United Kingdom,” said Zack Irani, CEO of Biomerica. “The UK represents an important addressable market given the high prevalence of H. pylori infection across Europe. This registration reflects our ongoing commitment to delivering innovative diagnostic solutions to patients and clinicians worldwide.”
About Biomerica (Nasdaq: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to the Company’s estimated future financial results, demand for the Company’s products, the Company’s ability to fulfill orders, regulatory clearance of the Company’s tests and products, and the possible success of our products once introduced into the market. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the safety and efficacy of the Company’s hp+detect™ test and actual safety and efficacy in patients; acceptance, adoption and sales of the hp+detect™ product within the medical community in the UK; regulatory approvals necessary prior to commercialization in additional countries, including FDA clearance; availability of the Company’s test kits and other products; capacity, resource and constraints on our suppliers; competition from other similar products and from competitors that have significantly more financial and other resources available to them; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold; and the Company’s ability to obtain patent protection and freedom to operate on any aspects of its diagnostic technologies. Accordingly, such future financial results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Investor Contact: Zack Irani | +1 949-645-2111 | investors@biomerica.com
Source: Biomerica, Inc.
FAQ**
What strategies is Biomerica Inc. (BMRA) implementing to ensure successful partnerships with UK diagnostic laboratories and expand its market share following the MHRA registration for hp+detect™?
How does Biomerica Inc. (BMRA) plan to address potential competition in the UK market for H. pylori diagnostics, especially given the established players in this space?
What measures is Biomerica Inc. (BMRA) taking to educate healthcare providers in the UK about the clinical advantages and benefits of its hp+detect™ product in tackling H. pylori infections?
How does Biomerica Inc. (BMRA) intend to leverage the increasing awareness of H. pylori as a Class 1 carcinogen to drive demand for its hp+detect™ test within the UK healthcare system?
**MWN-AI FAQ is based on asking OpenAI questions about Biomerica Inc. (NASDAQ: BMRA).
NASDAQ: BMRA
BMRA Trading
6.26% G/L:
$2 Last:
7,546 Volume:
$1.89 Open:
